Open an account

Connect Biopharma Holdings

CNTB · NASDAQ

$0.8752−$0.0246 (−2.73%)TodayMarket closed ·
Prev close $0.8998

About CNTB

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

Employees
64
Headquarters
San Diego, California
Listed
Mar 19, 2021
Sector
Health Care
Industry
Biotechnology
Website
connectbiopharm.com

CNTB key statistics

Market cap
55.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
9.95M
Volume
339.54K
Open price
$0.8949
High today
$0.9198
Low today
$0.875
52 Week high
$3.82
52 Week low
$0.8501

Connect Biopharma Holdings (CNTB) at a glance

Connect Biopharma Holdings (CNTB) last traded at $0.8752, with a market cap of 55.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.875 and $0.9198. The current price is 0.0% above the day's low and 4.8% below its high.

Volume so far is 339.54K shares, below the average of 9.95M shares a day.

Over the past year Connect Biopharma Holdings has ranged from $0.8501 to $3.82, and now sits 1% of the way up that range.

Connect Biopharma Holdings met or beat analyst EPS estimates in 5 of the last 7 quarters. In Q2 FY26 it reported -$0.27 per share against an estimate of -$0.3213.

The average analyst price target is $5.99, 584.7% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 8 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $5.99
Low
$4.04
Now
$0.8752
High
$9.45

CNTB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 7 quarters, by 59.1% on average.

  1. Q2 FY23: reported -$3.90 per share against an estimate of -$7.07
  2. Q1 FY25: reported -$0.19 per share against an estimate of -$1.92
  3. Q2 FY25: reported -$0.23 per share against an estimate of -$0.9192
  4. Q3 FY25: reported -$0.31 per share against an estimate of -$1.01
  5. Q4 FY25: reported -$0.2701 per share against an estimate of -$0.208
  6. Q1 FY26: reported -$0.34 per share against an estimate of -$0.2264
  7. Q2 FY26: reported -$0.27 per share against an estimate of -$0.3213

CNTB news

  • Avi Kapoor

    Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views

  • Vandana Singh

    Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

  • Press releaseGlobe Newswire

    3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours

  • Vandana Singh

    Why Is Connect Biopharma Stock Trading Lower on Tuesday?

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releasePRNewswire

    Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Similar companies

Companies in the same industry as Connect Biopharma Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.